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CASE REPORT

Clinical Utility of Molecular Profiling in Recurrent
Glioblastoma Multiforme
Rebecca P Bystrom MD,1 Pavalan Selvam MBBS,2 Jens Rueter MD,3 Honey V Reddi PhD,4 Christine LuEmerson MD1
1
Department of Neurology, Maine Medical Center, Portland ME, 2The Jackson Laboratory for Genomic Medicine, Farmington,
CT, 3The Maine Cancer Genomics Initiative, The Jackson Laboratory, Augusta, ME, 4Medical College of Wisconsin,
Milwaukee, WI

Introduction:

Glioblastoma multiforme (GBM) is the most common and aggressive primary malignant brain tumor found
in adults. GBM has limited therapeutic options. Initial tumor sampling establishes the histopathologic
diagnosis, identifies prognostic and therapeutic biomarkers, and provides an opportunity for molecular
profiling. By contrast, the utility of repeat tumor sampling and molecular profiling in recurrent GBM is not
well established.

Clinical Findings: We present a 69-year-old woman with GBM whose tumor recurred after standard treatment with
temozolomide (TMZ) and concurrent radiation, followed by adjuvant TMZ. This patient had a methylated
O6-methylguanine-DNA methyltransferase (MGMT) promoter, which ordinarily predicts a favorable
response to TMZ.
Main Diagnosis,
Therapeutic
Interventions,
and Outcomes:

Our patient’s recurrent tumor was rechallenged with TMZ based on persistent methylation of the MGMT
promoter. However, her tumor was refractory to TMZ, and she floridly progressed through multiple
treatments. We performed retrospective molecular profiling using next-generation sequencing (NGS)
on her recurrent tumor. The NGS results showed a TMZ hypermutation signature that confers resistance
to TMZ. This signature impacted our patient’s treatment plan in real time and prompted an immediate
discontinuation of TMZ.

Conclusions:

Advances in NGS provide further insight into the molecular landscape of GBM. As NGS becomes
more timely and cost-effective, molecular profiling of recurrent tumors could impact treatment decisions
through either avoiding a particular treatment paradigm or identifying a potential targetable mutation. For
this reason, we suggest that clinical practice routinely consider repeat biopsy and molecular profiling for
recurrent GBM.
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69-year-old woman presented with weakness
and paresthesia in her right lower extremity.
Magnetic resonance imaging (MRI) of the
brain showed enhancing lesions at the left frontoparietal junction and in the left occipito-parietal lobe
(Figure 1A and 1B). Complete resection of the left
occipital lesion revealed a isocitrate dehydrogenase
1 (IDH1) wildtype glioblastoma multiforme
(GBM) with a methylated O6-methylguanine-DNA
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methyltransferase (MGMT) promoter. Sequencing
was not performed as it was not routinely available
at that time. The patient proceeded with 6 weeks of
chemoradiation with TMZ and 12 cycles of adjuvant
TMZ. Bevacizumab, a recombinant humanized
monoclonal antibody against vascular endothelial
growth factor, was added for pseudo-progression.
Four months after treatment cessation, a
surveillance MRI showed a new enhancing lesion
in the contralateral frontal lobe (Figure 1C).
Repeat biopsy showed an MGMT methylated IDH1
wildtype recurrent GBM. Due to MGMT methylation
status, the patient was rechallenged with a hypo1
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fractionated course of chemoradiation with TMZ.
Yet the next MRI showed frank progression.
Bevacizumab was initiated as monotherapy before
reintroducing adjuvant TMZ. The patient progressed
with new enhancement in the left temporal lobe
(Figure 1D).
Molecular profiling (ActionSeq Plus/ActionSeq
Plus 2.0 by the Jackson Laboratory for Genomic
Medicine, Farmington, CT) of the patient’s recurrent
tumor revealed a ‘TMZ hypermutation signature.’1
This signature had an MSH6 mutation and 153
variants of unknown clinical significance and 261
genomic events with C>T transitions compared to
175 genomic events with C>T transitions in the
original tumor. Based on this hypermutation profile,
we discontinued TMZ and started pembrolizumab
(an antibody against programmed cell death
protein-1 and approved for MSH6 mutations) and
bevacizumab. Unfortunately, the tumor became too
invasive, with diffuse involvement of the brain. After
6 weeks of treatment, the patient was transitioned
to hospice.

DISCUSSION
Initial tumor sampling after surgical resection
of GBM enables histopathologic diagnosis and
molecular testing that assesses prognostic and
therapeutic biomarkers. The methylation status
of the MGMT promoter is one of the strongest
prognostic and predictive biomarkers in GBM.2 This
MGMT promoter methylation is associated with a
more favorable response to TMZ and improved
overall survival.2,3 When methylated, the MGMT
promoter silences the MGMT gene, which leads to
fewer successful repairs of O6-meG, the byproduct
of TMZ treatment.1

initial tumor. For instance, if the newly diagnosed
GBM has a methylated MGMT promoter, the
assumption is that the MGMT promoter will remain
methylated at recurrence and confer the same
prognostic and predictive value. However, different
molecular phenotypes can emerge at recurrence
and only be revealed with repeat molecular profiling.
To illustrate, the TMZ hypermutation phenotype is
associated with TMZ resistance. This phenotype
can emerge in recurrent GBMs that are initially
exposed to TMZ. When tumors with a methylated
MGMT promoter are treated with TMZ, the
increased O6-meG adducts are funneled toward
the mismatch repair pathway1. If tumor cells acquire
mutations in any component of this pathway, such
as the MSH6 gene, then G:C>A:T transitions
can accumulate, preventing tumor cell death.
This ‘TMZ hypermutation signature’1 creates a
survival advantage for the recurrent tumor. This
hypermutation signature can only be identified
by repeat biopsy and molecular profiling in the
recurrent tumor. Uncovering the hypermutation
signature can prevent further exposure to TMZ and
may dictate new treatment paradigms, including
those that incorporate immunotherapy.7

In recurrent GBM, there are limited treatment
options and no prognostic or therapeutic
biomarkers. Treatment often consists of adjusting
chemotherapeutic or biologic agents, and it may
involve reintroducing alkylating agents, such as
TMZ or lomustine. Bevacizumab, an antiangiogenic
agent, has also been approved for use in recurrent
GBM.4

The TMZ hypermutation signature cannot be
detected using conventional laboratory testing. Its
detection requires molecular profiling using highthroughput technologies such as next-generation
sequencing (NGS), which is now readily available
through academic and commercial laboratories.
NGS typically analyses 50 to 500 cancer-related
genes in parallel. It enables the identification of
new comprehensive biomarkers and also assesses
a tumor’s mutational burden. Various applications
of NGS can be developed to bypass concerns
regarding the timely application of this technology
in the clinical setting. For instance, to identify the
TMZ hypermutation phenotype, a rapid assessment
of the number of G:C>A:T transitions and tumor
mutational burden may suffice. Our local laboratory
estimates that the presence or absence of the
hypermutation phenotype could be communicated
to clinicians as quickly as 7 to 10 days.

Repeating a brain biopsy solely for the purpose of
molecular analysis of recurrent GBM is not routine
clinical practice. Surgery is reserved for significant
debulking as it confers a survival advantage.5,6 In
clinical practice, it is often assumed recurrent GBM
tumors harbor the same molecular features as the

There are technical limitations to using NGS
sequencing in GBM, including the amount of
tissue needed for testing and the degree of
neoplastic content in tumor samples. Cost is also a
consideration if incorporating additional molecular
testing into the management algorithm. While NGS
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can be cost-effective, the reimbursement model in
clinical practice has not been fully established.8
The utility of repeat biopsy for molecular profiling
in recurrent GBM has not been previously
established. We present a case in which repeat
molecular profiling could have provided guidance
for treatment. Despite the change in treatment,
the patient rapidly progressed, underscoring the

challenges in treating recurrent GBM. Earlier
application of pembrolizumab may have been
more beneficial. Timely incorporation of molecular
profiling for recurrent GBM may guide appropriate
targeting of mutations or avoidance of specific
chemotherapeutic agents.
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Figure 1. Axial post-contrast T1 MRI brain. (A) Original MRI showed enhancing lesion in left occipital
lobe. This was treated with gross total resection. (B) Original MRI showed separate enhancing lesion in
the left frontal lobe in the original MRI brain. (C) Surveillance MRI showed first recurrence in the right
frontal lobe. Review of prior radiation map showed that this area was outside of the radiation field. This
lesion was treated with gross total resection. (D) Surveillance MRI showed second recurrence in the left
temporal lobe. MRI, magnetic resonance imaging.
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